{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parvovirus-b19-infection/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field bd6f2459-da0e-45c7-a26f-3ab8a892aa75 --><h2>When should I suspect parvovirus B19 infection?</h2><!-- end field bd6f2459-da0e-45c7-a26f-3ab8a892aa75 -->","summary":"","htmlStringContent":"<!-- begin item ee8e137c-7728-4ed0-bfa9-d2b7378a0615 --><!-- begin field feae598e-f173-4dc8-a63f-748f7ae9c4d7 --><p><strong>In healthy children, the diagnosis of parvovirus B19 infection is usually made on clinical grounds.</strong></p><ul><li><strong>Suspect infection in children if they present with an acute biphasic illness with a characteristic diffuse erythematous facial rash, appearing on one or both cheeks (resembling a 'slapped cheek').</strong><ul><li>The rash may be preceded by 2–5 days of prodromal symptoms, such as low-grade fever, nasal discharge, headache, myalgia, and mild nausea and/or diarrhoea.</li><li>The facial rash usually fades after 1–2 weeks and is often associated with perioral and periorbital pallor.</li><li>An erythematous maculopapular rash on the trunk, back, and limbs may develop a few days after the facial rash, which fades to produce a lace-like, reticular rash. This usually resolves over a few days or weeks. There may be associated itching, for example of the soles of the feet.</li><li>Rarely, there may be associated arthropathy of the knees and ankles.</li></ul></li></ul><p><strong>In healthy adults, it is difficult to make a diagnosis of parvovirus B19 infection on clinical grounds, as symptoms may be atypical, it may mimic <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/diagnosis/differential-diagnosis/\">other conditions</a>, and 25–50% of adults are asymptomatic.</strong></p><ul><li><strong>Suspect infection in adults if they present with a history of contact with parvovirus B19 infection (usually in a child), or if there is a known local outbreak. The infectivity period is 7–10 days before a rash develops, to the day after the onset of rash, in a contact.</strong><ul><li>Prodromal symptoms (such as mild fever, malaise, myalgia, and headache) may appear about a week after contact with the infection.</li><li>The characteristic facial rash seen in children is rare in adults, but 2–3 weeks after the first prodromal symptoms, a maculopapular rash on the trunk, back, and limbs may develop, which fades to produce a lace-like, reticular rash. This usually resolves within a week.</li><li>There may be a symmetrical polyarthropathy following the appearance of the rash, which is more common in women. This typically:<ul><li>Affects the proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints of the hands, and less commonly the wrists, knees, and ankles. The joints may be painful, swollen, and stiff.</li><li>Lasts 1–3 weeks, but rarely may persist for months or years.</li></ul></li></ul></li></ul><p><strong>Note: consider parvovirus B19 infection in people who are immunocompromised or who have an underlying haematological disorder, who present with sudden-onset or severe <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/background-information/complications/\">anaemia</a>.</strong></p><!-- end field feae598e-f173-4dc8-a63f-748f7ae9c4d7 --><!-- end item ee8e137c-7728-4ed0-bfa9-d2b7378a0615 -->","topic":{"id":"a0e6adce-f85f-55b0-8d7f-3b5e75836d40","topicId":"3ea4cf87-3eee-4e3f-a6d0-b0ee3a4ee3ad","topicName":"Parvovirus B19 infection","slug":"parvovirus-b19-infection","lastRevised":"Last revised in February 2017","chapters":[{"id":"c45face5-dc30-586a-b7ca-3b24305bd068","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc09231e-bb7a-5379-aeec-7c830288098e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes"},{"id":"af1bc49c-d614-521b-b6f3-ad084fc2aed9","slug":"update","fullItemName":"Update"}]},{"id":"7c9f0c10-cf1d-5723-856f-e0bc2d270210","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb1635ce-433b-5f39-a93a-27b4488878c5","slug":"goals","fullItemName":"Goals"},{"id":"3c7eed51-287a-5bcb-8519-40ef7f5784aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"291f85a1-8911-59d4-82d6-62ce4daff1c0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e66b8854-eb00-59b9-85d9-f50343f36470","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce817770-4fbe-5b47-b4ed-56b723012488","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"faa5c5db-5837-5cbd-8e56-78bc7ac42137","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afcf1b63-41ac-5295-91b5-4e19bc828249","slug":"definition","fullItemName":"Definition"},{"id":"60a93741-3863-58bb-8394-a33804062373","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications"},{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations"},{"id":"7daba43a-1410-5703-8a94-b6530a5dfccc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b0275eae-f19c-57fb-834c-03df7c6dcea3","fullItemName":"Management","slug":"management","subChapters":[{"id":"73c2e9d4-b567-504f-9b28-36966a247590","slug":"children-adults-not-pregnant","fullItemName":"Scenario: Children and adults (not pregnant)"},{"id":"25b4fecb-ae9d-58f7-ad14-7ace595c0800","slug":"pregnant-women","fullItemName":"Scenario: Pregnant women"}]},{"id":"bdf3d270-5563-5eb4-804f-68fce2e7e7dd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"73875656-8429-5584-82e6-d06c0a5f52ea","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8dc117ba-c373-5ee0-a7aa-fc63a62a7067","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"24bd5691-28ce-53b1-be8b-f0e51e40db4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b35b969-66a8-5431-900a-a524f0bf1a89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63ad51a8-8325-52f2-a254-ed3ccae9f508","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"174a35a7-6fa3-58ef-9e06-6325d5f0111b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c6c0fc6f-31f8-5681-bbce-4ed5b6b16e4e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"e187340a-b012-54f6-8d6e-94723481ed60","slug":"basis-for-recommendation-327","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 0a6169dd-f86d-4b4e-9dc2-5b706129ff5f --><h3>Basis for recommendation</h3><!-- end field 0a6169dd-f86d-4b4e-9dc2-5b706129ff5f -->","summary":null,"htmlStringContent":"<!-- begin item 3273ba90-c361-43c9-8fdd-51aacdebeb85 --><!-- begin field 579554ad-1888-4960-b311-a9f3a101c034 --><p>The information on when to suspect parvovirus B19 infection is based on expert opinion in the Public Health England (PHE) document <em>Parvovirus B19: guidance, data and analysis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">PHE, 2012</a>], expert opinion in the Society of Obstetricians and Gynaecologists of Canada clinical practice guideline <em>Parvovirus B19 infection in pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">SOGC, 2014</a>], expert opinion in the UK National Screening Committee document <em>Parvovirus B19 infection in pregnancy. A brief review of the literature</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">UK National Screening Committee, 2014</a>], and expert opinion in a review article on human parvovirus B19 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">American Association of Blood Banks, 2009</a>] and a review article on common skin conditions in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Allmon, 2015</a>].</p><!-- end field 579554ad-1888-4960-b311-a9f3a101c034 --><!-- end item 3273ba90-c361-43c9-8fdd-51aacdebeb85 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}